Thymosin Alpha-1
Immune & Anti-InflammatoryAlso known as: Ta1, Thymalfasin, Zadaxin, Thymosin Alpha 1
Mechanism
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that serves as a master regulator of immune function. It enhances the body's ability to fight infections and detect abnormal cells by boosting T-cell function, natural killer cell activity, and dendritic cell maturation. It has been used clinically in over 30 countries for hepatitis B and C, as an immune booster in immunocompromised patients, and as an adjunct to cancer immunotherapy.
Technical detail
Thymosin Alpha-1 is a 28-amino-acid peptide with an acetylated N-terminus, originally isolated from thymic tissue (Thymosin Fraction 5). It acts as a biological response modifier through activation of Toll-like receptors (TLR2, TLR9) on dendritic cells and macrophages, promoting MHC class I expression, CD8+ cytotoxic T-cell maturation, and Th1 cytokine polarization (IFN-g, IL-2). It simultaneously enhances NK cell cytotoxicity and antibody responses while modulating regulatory T-cell activity to prevent excessive inflammation.
Effects
**Immune System — Adaptive Immunity (Tier 1 — Extensive Clinical Data):** Thymosin alpha-1 (Ta1) is a 28-amino acid peptide naturally produced by thymic epithelial cells. It is the most clinically studied immune-modulating peptide in the world. Primary mechanisms: (1) activates dendritic cells via TLR9 signaling — enhances antigen presentation and T-cell priming; (2) promotes T-cell maturation and differentiation in the thymus; (3) enhances CD4+ and CD8+ T-cell function; (4) increases NK cell cytotoxicity; (5) stimulates IL-2 and IFN-alpha/gamma production; (6) restores Th1/Th2 balance in immunocompromised states. **Immune System — Innate Immunity (Tier 1):** Ta1 also modulates innate immunity: enhances macrophage phagocytosis, promotes dendritic cell maturation and MHC class I/II expression, increases complement activity. Acts as an endogenous "immune trainer" — restoring immune competence rather than simply stimulating it (immunomodulator, NOT an immunostimulant in the traditional sense). **Antiviral Effects (Tier 1):** Direct enhancement of antiviral immune responses. In hepatitis B: restores HBV-specific T-cell responses suppressed by chronic infection. In hepatitis C: enhances IFN-alpha therapy response rates. Broad antiviral immune enhancement applicable to: HBV, HCV, HIV (adjunct), CMV, EBV, and respiratory viruses. **Anti-tumor Immunity (Tier 1-2):** Enhances anti-tumor immune surveillance. Increases tumor-specific cytotoxic T lymphocyte (CTL) activity. Augments NK cell-mediated tumor killing. When combined with chemotherapy or checkpoint inhibitors, may improve response rates by restoring immune function suppressed by the tumor microenvironment or chemo-induced immunosuppression. **Vaccine Enhancement (Tier 2):** Acts as an immune adjuvant — co-administration with vaccines enhances antibody and T-cell responses. Particularly valuable in immunocompromised patients (elderly, HIV+, cancer patients) who have suboptimal vaccine responses. **Sepsis/Critical Illness (Tier 2):** In sepsis, Ta1 addresses the immunoparalysis/immunosuppression phase that follows the initial cytokine storm. Restores HLA-DR expression on monocytes (a key marker of immune competence in sepsis), enhances pathogen clearance, and reduces secondary infection rates.
Practitioner Guide
**Hepatitis B Treatment (Approved Indication in 35+ Countries):** - Marketed as Zadaxin in Asia, South America, Europe - Dose: 1.6mg SC twice weekly for 6-12 months - Often combined with nucleos(t)ide analogs (entecavir, tenofovir) - Combination therapy achieves higher HBeAg seroconversion rates than antivirals alone - Sustained virological response: 30-40% of patients achieve durable HBsAg clearance (vs. ~10% with antivirals alone) - Best responders: high ALT, low HBV DNA, genotype B (vs. C) **Hepatitis C Treatment (Pre-DAA Era, Still Relevant in Some Settings):** - Historical use: Ta1 1.6mg SC 2x/week + interferon-alpha + ribavirin → improved SVR rates vs. IFN + ribavirin alone - In the era of direct-acting antivirals (DAAs): Ta1 may have adjunctive role in difficult-to-treat cases or in resource-limited settings where DAAs are unavailable - Some practitioners use Ta1 post-DAA cure to restore immune function in patients with cirrhosis/advanced liver disease **Cancer Adjuvant Protocols:** - Dose: 1.6mg SC daily for 5-7 days before and during chemotherapy cycles, then 1.6mg SC 2x/week between cycles - Tumor types with most evidence: hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma - HCC: Ta1 combined with TACE (transarterial chemoembolization) significantly improves overall survival in multiple Chinese RCTs - NSCLC: Ta1 + chemotherapy improves immune parameters and quality of life; some studies show improved progression-free survival - Melanoma: Ta1 + dacarbazine or interferon showed improved response rates in European trials (Garaci et al.) - With checkpoint inhibitors: emerging rationale — Ta1 restores T-cell function in the immunosuppressive tumor microenvironment, potentially enhancing PD-1/PD-L1 blockade response. Case series showing benefit; no completed RCTs yet **COVID-19 Protocol (Widely Used in China During Pandemic):** - Chinese National Health Commission included Ta1 in treatment guidelines for severe COVID-19 - Dose: 1.6mg SC daily for 7-14 days in hospitalized patients - Rationale: COVID-19 causes lymphopenia and T-cell exhaustion → Ta1 restores T-cell counts and function - Multiple Chinese studies (2020-2021): Ta1 reduced mortality in severe COVID by 30-60% in retrospective analyses - Also used prophylactically in healthcare workers during peak pandemic: 1.6mg SC 2x/week **Functional Medicine — Chronic Infection Protocols:** - Chronic Lyme disease: Ta1 1.6mg SC 2x/week for 3-6 months as immune support alongside antimicrobial therapy - Chronic EBV/CMV reactivation: Ta1 1.6mg SC 2x/week for 2-3 months; monitor viral titers - Chronic fatigue syndrome / ME-CFS (with suspected immune dysfunction): Ta1 1.6mg SC 2x/week for 3-6 months; assess energy, NK cell function, cytokine panels - CIRS/mold illness: Ta1 as immune restoration agent — used after initial binder/avoidance phase; 1.6mg SC 2x/week for 2-3 months - HIV adjunct: Ta1 enhances CD4 recovery alongside antiretroviral therapy in some clinical settings **Dosing and Practical Notes:** - Standard dose: 1.6mg SC (this is the Zadaxin pharmaceutical dose — nearly all clinical evidence is at this dose) - Injection: SC in abdomen or deltoid; well-tolerated with minimal injection site reactions - Can be given long-term (months to years) without evidence of tolerance or immunosuppressive rebound - NO immunosuppressive effects — safe in autoimmune patients (unlike many immunostimulants) - Does NOT cause cytokine storm or excessive immune activation - No significant drug interactions documented - Monitoring: CBC with differential, CD4/CD8 ratio, NK cell count, IgG subclasses at baseline and every 2-3 months
Dosing Protocols
- Dose
- 1600mcg
- Frequency
- 2x per week (e.g., Mon/Thu)
- Timing
- Morning on an empty stomach
- Route
- subcutaneous
- Cycle
- 4-24 weeks
Morning dosing aligns with circadian immune rhythm; T-cell modulation and dendritic cell activation benefit from consistent twice-weekly scheduling matching pharmaceutical Zadaxin protocol
Contraindications & Cautions
- hard stop — Immunosuppressive medicationsThymosin alpha-1 is an immune-stimulating peptide that enhances T-cell function, dendritic cell maturation, and NK cell activity. Use with immunosuppressive drugs (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids) creates directly conflicting mechanisms that may reduce immunosuppression efficacy or cause unpredictable immune responses.Action: Do not use concurrently with immunosuppressive medications. The immune-stimulating effects directly oppose the therapeutic goal of immunosuppression and may precipitate graft rejection or autoimmune flares.
- hard stop — Organ transplant recipientThymosin alpha-1 stimulates immune function including T-cell maturation and activation. In organ transplant recipients, immune stimulation may trigger acute or chronic graft rejection, even in patients on adequate immunosuppression.Action: Absolutely contraindicated in organ transplant recipients. Immune stimulation poses direct risk of graft rejection and life-threatening complications.
- hard stop — PregnancyNo adequate human safety data during pregnancy. Immune modulation during pregnancy could affect maternal-fetal immune tolerance and potentially trigger complications.Action: Do not use during pregnancy.
- hard stop — BreastfeedingNo data on excretion in breast milk. Immune-modulating effects on nursing infant unknown.Action: Do not use while breastfeeding.
- hard stop — Under 18 years of agePeptide protocols are not designed for pediatric use. Immune modulation may interfere with normal immune system maturation.Action: Do not provide peptide protocols to individuals under 18.
- requires physician — Autoimmune diseaseThymosin alpha-1 enhances immune surveillance and T-cell function. In patients with autoimmune conditions, this immune stimulation may exacerbate the autoimmune response and trigger disease flares.Action: Requires specialist evaluation. Use only under supervision of immunologist or rheumatologist. Monitor autoimmune markers closely.
Evidence
- moderate
Xu H, Li F, Li B, Yang D, Liu T, Xia Y, Hua H, Li Q, Wang J, Liu H, Xu Z (2026) — BMC Medicine — PMID: 41749205
In 30 patients with stage III gastric or gastroesophageal junction adenocarcinoma, neoadjuvant serplulimab plus SOX plus thymalfasin achieved pathological complete response in 30.0% and major pathological response in 56.7%, with grade 3 or higher adverse events in 26.7%. Immune profiling suggested enhanced CD8-positive T-cell activation and improved antigen-presentation signaling, supporting thymosin alpha-1 as an immunomodulatory adjunct rather than standalone anticancer therapy.
- strong
Li ZH, Wu LL, Zhu YQ, Hu ZX, Meng SB, Lei ZY, Cao HJ, Wang JL, Chen JF, Zhang J, Lin BL (2026) — Immunopharmacology and Immunotoxicology — PMID: 41887933
In an open-label randomized trial of 73 patients with HBV-related acute-on-chronic liver failure, thymosin alpha-1 plus standard medical therapy improved 90-day transplant-free survival versus standard care alone. Benefit was associated with reduced regulatory T-cell excess, moderation of late hyperinflammation, and preservation of early immune activation, suggesting immune rebalancing as the mechanism.
- moderate
Thymosin alpha 1 — a peptide immune modulator with a broad spectrum of clinical applications
Tuthill C, Rios I, McBeath R (2010) — Clinical and Experimental Pharmacology
Thymosin alpha-1 acts as a biological response modifier enhancing T-cell maturation, dendritic cell function, and NK cell activity. Clinical evidence supports use in chronic hepatitis B/C, as adjunct to cancer vaccines, and in immunocompromised patients. Approved in over 35 countries for hepatitis B and as immune adjuvant. Favorable safety profile with no significant drug interactions.
- moderate
Thymalfasin (thymosin-alpha-1) therapy in patients with chronic hepatitis B
Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS (1998) — Hepatology — PMID: 9537454
Thymosin alpha-1 (thymalfasin) 1.6 mg subcutaneously twice weekly for 6 months produced sustained HBeAg seroconversion and HBV DNA clearance in significantly more chronic hepatitis B patients than placebo at 12-month follow-up. Well-tolerated with minimal side effects compared to interferon-alpha therapy.
- moderate
Thymosin alpha 1 and interferon alpha for the treatment of chronic hepatitis C
Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D (1998) — Hepatology — PMID: 9537455
Combination of thymosin alpha-1 with interferon-alpha showed improved sustained virological response rates in chronic hepatitis C compared to interferon alone. The combination was well-tolerated and suggested synergistic immune-modulating effects through enhanced T-cell and NK cell activation.
Stacks featuring this peptide
Comprehensive recovery protocol for post-surgical healing. BPC-157 accelerates wound closure, tendon/ligament repair, and reduces surgical inflammation via VEGF and nitric oxide pathways. TB-500 provides systemic tissue repair and angiogenesis (new blood vessel formation to the surgical site). Thymosin Alpha-1 boosts immune defense during the immunosuppressed post-surgical window — critical for preventing post-op infections. GHK-Cu resets gene expression toward wound healing patterns, stimulates collagen I/III deposition, and the copper ion has direct antimicrobial properties. Four distinct healing mechanisms working simultaneously.
SS-31 (Elamipretide) targets cardiolipin in the inner mitochondrial membrane, restoring electron transport chain efficiency and reducing mitochondrial ROS — addressing perhaps the most fundamental driver of aging at the cellular level. Thymosin Alpha-1 restores thymic function and T-cell maturation, directly combating immunosenescence. Together they address the two pillars of aging: mitochondrial decline and immune system deterioration.
For autoimmune conditions with a gut permeability component (Crohn's, ulcerative colitis, celiac, rheumatoid arthritis with gut involvement). KPV (alpha-MSH tripeptide) is a potent NF-κB inhibitor that directly suppresses the inflammatory cascade driving autoimmune flares. BPC-157 heals the gut mucosa and modulates the nitric oxide system, addressing the tissue damage from chronic inflammation. Thymosin Alpha-1 rebalances T-cell subsets — shifting from Th17/pro-inflammatory toward Treg/regulatory phenotype. Larazotide seals tight junctions, reducing the gut permeability that allows antigenic proteins to trigger systemic immune responses. The "leaky gut → immune activation → tissue damage" cycle is addressed at every node.
Thymosin Alpha-1 (T-cell maturation, NK cell activation, approved in 35+ countries) + LL-37 (broad-spectrum antimicrobial, anti-biofilm, innate immunity) + Thymalin (thymic restoration, comprehensive immune rebalancing). Triple approach: innate defense (LL-37), adaptive immunity (TA1), and thymic rejuvenation (Thymalin).
A comprehensive thymic reconstitution and innate immune restoration protocol. Thymosin Alpha-1 (approved in 35+ countries) drives T-cell maturation and NK cell activation — the adaptive immune system's primary effectors. Thymalin (thymus extract) provides the full spectrum of thymic hormones to restore age-related thymic involution. Thymulin (FTS-Zn, requires zinc cofactor) specifically promotes T-cell differentiation marker expression (CD2, CD3, CD4). LL-37 (human cathelicidin) activates the innate immune system — direct antimicrobial activity, biofilm disruption, and chemotaxis of immune cells. Together: rebuild the thymus (Thymalin), mature new T-cells (Tα1 + Thymulin), and arm the front-line defense (LL-37). Designed for post-infection immune rebuilding, age-related immune decline, or recurrent infection patterns.
Research Summary
**Tier 1 — Approved Pharmaceutical (35+ Countries):** - Zadaxin (thymalfasin/thymosin alpha-1 1.6mg): approved in >35 countries for hepatitis B and as an immune modulator - NOT FDA-approved in the US (SciClone Pharmaceuticals sought FDA approval; approved in China, Italy, and many other countries) - Hepatitis B: >20 RCTs showing enhanced seroconversion rates when combined with standard antivirals - Meta-analyses (Cochrane): Ta1 + interferon vs. interferon alone for HBV — significantly higher HBeAg seroconversion (OR 1.56) and HBV DNA clearance **Tier 2 — Extensive Published Clinical Evidence:** - Cancer adjuvant: >30 clinical trials (mostly Chinese and Italian) across HCC, NSCLC, melanoma, breast cancer - HCC + TACE: 3 Chinese RCTs (n=200-400 each) showing 15-25% improvement in 1-year survival with Ta1 adjunct - NSCLC + chemotherapy: improved quality of life, immune parameters; some studies show improved PFS (Garaci, Maio et al.) - Sepsis: RCTs in China showing reduced 28-day mortality with Ta1 in severe sepsis (Li et al., Crit Care 2014, n=361) - COVID-19: retrospective studies (Wu et al., 2020; Liu et al., 2020) showing reduced mortality in severe COVID; included in Chinese national treatment guidelines **Tier 2 — Vaccine Adjuvant:** - Enhances influenza vaccine response in elderly (Gravenstein et al., J Am Geriatr Soc 1989) - Enhances hepatitis B vaccine response in immunocompromised patients (dialysis patients, HIV+) **Tier 3 — Emerging/Experimental:** - Ta1 + checkpoint inhibitors (anti-PD-1/PD-L1): case series and early-phase trials showing potential synergy - Ta1 in aging/longevity: proposed as immune rejuvenation agent; limited clinical evidence specific to anti-aging - Ta1 for chronic fatigue/ME-CFS: practitioner-level evidence, no RCTs - Oral/sublingual Ta1 formulations in development (peptide nanoparticle delivery) - Ta1 as bioterrorism countermeasure: US military research on immune enhancement for biological threat preparedness